What Is Celiac Disease

Celiac disease is a genetically predisposed autoimmune condition in which the ingestion of gluten, a protein found in wheat, barley, and rye, triggers an immune response that damages the lining of the small intestine. The resulting destruction of intestinal villi reduces the body's capacity to absorb essential nutrients. It affects roughly one percent of the global population, though many cases remain undiagnosed for years or decades.

The small intestine is the primary site where the body absorbs vitamins, minerals, fatty acids, and amino acids. When celiac disease flattens the villi that perform this work, deficiencies in iron, calcium, vitamin D, B12, folate, and zinc become common even when dietary intake appears sufficient. These deficiencies ripple outward: bone density declines, immune regulation falters, energy metabolism slows, and neurological function can deteriorate. Because the damage accumulates silently in many people, the condition often produces years of subclinical harm before diagnosis.

From a longevity perspective, celiac disease matters because it sustains two processes that accelerate biological aging: chronic low-grade inflammation and impaired nutrient status. The inflammatory cascade triggered by gluten exposure upregulates pro-inflammatory cytokines, increases intestinal permeability (often called "leaky gut"), and raises allostatic load. Meanwhile, nutrient malabsorption undermines the raw materials cells need for DNA repair, mitochondrial function, and antioxidant defense. Unmanaged celiac disease is also associated with a higher incidence of other autoimmune disorders, osteoporosis, and certain gastrointestinal cancers. Identifying and addressing it early removes a significant source of systemic interference.

Celiac disease begins with a genetic prerequisite. Nearly all affected individuals carry HLA-DQ2 or HLA-DQ8 gene variants, which encode specific immune system molecules on antigen-presenting cells. These molecules happen to bind fragments of gluten proteins with high affinity. Carrying these genes is necessary but not sufficient; an environmental trigger, such as an infection, gut dysbiosis, or physiological stress, typically initiates the autoimmune cascade.

When a person with celiac disease ingests gluten, the protein is partially digested into peptide fragments, particularly from the gliadin component. These peptides cross the intestinal epithelium, sometimes aided by increased permeability mediated by the protein zonulin. Once in the lamina propria (the tissue layer beneath the intestinal lining), the enzyme tissue transglutaminase (tTG) chemically modifies these peptides through deamidation, making them bind even more tightly to HLA-DQ2 or HLA-DQ8 molecules. Antigen-presenting cells then display these modified peptides to T cells, which mount a targeted immune response. This response includes the release of inflammatory cytokines, activation of intraepithelial lymphocytes that directly attack intestinal epithelial cells, and the production of antibodies against both gliadin and tissue transglutaminase itself.

The net result is progressive destruction of the intestinal villi, a process called villous atrophy, accompanied by crypt hyperplasia (an overgrowth of the deeper intestinal glands as the body tries to compensate). The flattened mucosal surface dramatically reduces absorptive area. Simultaneously, the compromised barrier allows larger molecules to pass into the bloodstream, fueling systemic immune activation. This cycle persists as long as gluten is present in the diet; once gluten is completely removed, the inflammatory stimulus ceases and the intestinal lining can gradually regenerate, though the timeline varies from months to years depending on the severity and duration of damage.

Celiac disease presents across a wide clinical spectrum. Classic gastrointestinal symptoms include chronic diarrhea, bloating, abdominal pain, and steatorrhea (fatty stools). Many individuals, however, present with predominantly extraintestinal symptoms: persistent iron-deficiency anemia unresponsive to oral supplementation, unexplained fatigue, recurrent mouth ulcers (aphthous stomatitis), joint pain, and a characteristic itchy skin rash called dermatitis herpetiformis. Neurological manifestations such as peripheral neuropathy, balance difficulties, and cognitive fog (sometimes called "gluten brain") occur in a meaningful subset of patients.

In children, failure to thrive, delayed puberty, and short stature may be presenting features. In adults, osteoporosis or osteopenia discovered earlier than expected for age can be the first clue. Some individuals are entirely asymptomatic and are identified through screening prompted by a family member's diagnosis or the presence of another autoimmune condition such as type 1 diabetes or Hashimoto's thyroiditis. The wide variability in presentation is a key reason celiac disease remains underdiagnosed; the average time from symptom onset to diagnosis has historically been measured in years rather than months.

The standard first-line test is the tissue transglutaminase IgA (tTG-IgA) antibody, which has both high sensitivity and specificity when performed while the individual is consuming gluten. A total serum IgA should be measured concurrently, because roughly two to three percent of people with celiac disease have selective IgA deficiency, which would produce a false-negative tTG-IgA result. In IgA-deficient individuals, deamidated gliadin peptide IgG (DGP-IgG) or tTG-IgG antibodies are used instead.

When serology is positive, an upper endoscopy with multiple biopsies of the duodenum is typically performed to confirm the diagnosis by demonstrating villous atrophy, crypt hyperplasia, and increased intraepithelial lymphocytes. HLA-DQ2/DQ8 genetic testing is useful mainly for its negative predictive value: if neither variant is present, celiac disease is extremely unlikely. This makes genetic testing most helpful in ambiguous cases or for screening family members. Newer point-of-care rapid antibody tests exist, but they are generally less sensitive than laboratory-based serology and should not be used as the sole diagnostic tool. Critically, all serological tests require the individual to be eating gluten regularly for at least several weeks before testing; premature dietary restriction renders results unreliable.

Restoring gut health after a celiac diagnosis centers on three phases: removal of the trigger, repair of the damaged tissue, and repletion of depleted nutrients. The first phase, complete and permanent elimination of gluten, is both the treatment and the prerequisite for everything that follows. Even trace contamination (estimated thresholds as low as 10 to 50 milligrams per day) can sustain subclinical inflammation and prevent full mucosal recovery.

Once gluten is removed, the intestinal epithelium begins to regenerate. Supporting this process involves ensuring adequate intake of nutrients that facilitate mucosal repair: zinc, vitamin A, L-glutamine, and omega-3 fatty acids are commonly emphasized in functional approaches, though evidence for supplemental glutamine specifically in celiac recovery is limited. A whole-foods diet rich in non-processed, naturally gluten-free foods (vegetables, fruits, legumes, quality proteins, and healthy fats) provides the micronutrient density the healing gut needs. Fermented foods and targeted probiotics may support microbial diversity, which is often reduced in active celiac disease.

The repletion phase addresses the deficiencies that accumulated during the period of active disease. Iron, vitamin D, B12, folate, calcium, and zinc are the most commonly depleted nutrients and should be measured and supplemented as needed. In the early months, when absorptive capacity is still recovering, sublingual, liquid, or injectable forms may achieve better results than standard tablets. Follow-up serological testing at six to twelve months confirms that antibody levels are normalizing, and some clinicians recommend a repeat biopsy at one to two years to verify histological healing, particularly in adults who may heal more slowly than children.

Celiac disease is one of the most thoroughly studied autoimmune conditions. The genetic basis (HLA-DQ2/DQ8), the role of tissue transglutaminase, and the immunological cascade are well characterized through decades of immunology and gastroenterology research. Large epidemiological studies have established its prevalence at roughly one percent of populations with European ancestry, with significant rates of underdiagnosis. Serological screening using tTG-IgA has been validated across multiple large cohorts with high sensitivity and specificity, though small-intestinal biopsy remains the diagnostic standard.

Research gaps remain in several areas. The precise environmental triggers that activate disease in genetically susceptible individuals are not fully mapped; viral infections, particularly reovirus, have been implicated in animal models and some human cohort studies, but causality is not established. The phenomenon of refractory celiac disease, in which the intestine does not heal despite strict gluten avoidance, is poorly understood and has limited treatment options. Several pharmacological interventions are in clinical trials, including larazotide acetate (a zonulin antagonist intended to reduce intestinal permeability) and gluten-degrading enzymes, but none have yet demonstrated sufficient efficacy to replace the gluten-free diet. Long-term outcome data on how completely the gut recovers, particularly in individuals diagnosed after years of untreated disease, are still being refined. The intersection of celiac disease with biological aging markers, such as epigenetic clocks and inflammatory indices, is an emerging area with limited but suggestive data.

The primary risk of celiac disease is the consequence of not identifying or not fully treating it: sustained malabsorption, chronic inflammation, increased intestinal permeability, and elevated risk of osteoporosis, other autoimmune conditions, and certain lymphomas. A strict gluten-free diet itself carries few inherent risks, though poorly planned versions can be low in fiber and B vitamins if they rely heavily on processed gluten-free products. Self-diagnosis without serological and histological confirmation is unreliable, as symptoms overlap with many other conditions; removing gluten before testing can mask the diagnosis. Individuals with confirmed celiac disease should have periodic follow-up to ensure mucosal healing and nutrient repletion, ideally guided by a clinician familiar with the condition.